{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T22:46:28Z","timestamp":1785883588760,"version":"3.56.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T00:00:00Z","timestamp":1475452800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1007\/s00774-016-0779-2","type":"journal-article","created":{"date-parts":[[2016,10,3]],"date-time":"2016-10-03T06:58:17Z","timestamp":1475477897000},"page":"456-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report"],"prefix":"10.1007","volume":"35","author":[{"given":"Hitoshi","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Kakihata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sawako","family":"Yatomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeru","family":"Nihojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Tabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,10,3]]},"reference":[{"key":"779_CR1","unstructured":"Statistics Bureau, Ministry of Internal Affairs and Communications (2015) Current population estimates as of September 15, 2015 (65\u00a0years old and over) (in Japanese)"},{"key":"779_CR2","unstructured":"[No authors listed] (2000) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement 17:1\u201345"},{"key":"779_CR3","doi-asserted-by":"crossref","first-page":"438","DOI":"10.6061\/clinics\/2014(06)12","volume":"69","author":"V Nardone","year":"2014","unstructured":"Nardone V, D\u2019Asta F, Brandi ML (2014) Pharmacological management of osteogenesis. Clinics (Sao Paulo) 69:438\u2013446","journal-title":"Clinics (Sao Paulo)"},{"key":"779_CR4","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","volume":"285","author":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy","year":"2001","unstructured":"NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785\u2013795","journal-title":"JAMA"},{"key":"779_CR5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11657-012-0109-9","volume":"7","author":"H Orimo","year":"2012","unstructured":"Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis\u2014executive summary. Arch Osteoporos 7:3\u201320","journal-title":"Arch Osteoporos"},{"key":"779_CR6","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF03256927","volume":"31","author":"JM Quesada G\u00f3mez","year":"2011","unstructured":"Quesada G\u00f3mez JM, Blanch Rubi\u00f3 J, D\u00edaz Curiel M, D\u00edez P\u00e9rez A (2011) Calcium citrate and vitamin D in the treatment of osteoporosis. Clin Drug Invest 31:285\u2013298","journal-title":"Clin Drug Invest"},{"key":"779_CR7","doi-asserted-by":"crossref","first-page":"F8","DOI":"10.1152\/ajprenal.00336.2004","volume":"289","author":"AS Dusso","year":"2005","unstructured":"Dusso AS, Brown AJ, Slatopolsky E (2005) Vitamin D. Am J Physiol Renal Physiol 289:F8\u2013F28","journal-title":"Am J Physiol Renal Physiol"},{"issue":"suppl 1","key":"779_CR8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000065376","volume":"92","author":"M Fukagawa","year":"2002","unstructured":"Fukagawa M, Kurokawa K (2002) Calcium homeostasis and imbalance. Nephron 92(suppl 1):41\u201345","journal-title":"Nephron"},{"key":"779_CR9","doi-asserted-by":"crossref","first-page":"5031","DOI":"10.1210\/jc.2004-2552","volume":"90","author":"T Matsumoto","year":"2005","unstructured":"Matsumoto T, Miki T, Hagino H, Sugimoto T, Okamoto S, Hirota T, Tanigawara Y, Hayashi Y, Fukunaga M, Shiraki M, Nakamura T (2005) A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial. J Clin Endocrinol Metab 90:5031\u20135036","journal-title":"J Clin Endocrinol Metab"},{"key":"779_CR10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures\u2013a randomized, active comparator, double-blind study. Bone (NY) 49:605\u2013612","journal-title":"Bone (NY)"},{"key":"779_CR11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00774-015-0710-2","volume":"34","author":"K Ebina","year":"2016","unstructured":"Ebina K, Noguchi T, Hirao M, Kaneshiro S, Tsukamoto Y, Yoshikawa H (2016) Comparison of the effects of 12\u00a0months of monthly minodronate monotherapy and monthly minodronate combination therapy with vitamin K2 or eldecalcitol in patients with primary osteoporosis. J Bone Miner Metab 34:243\u2013250","journal-title":"J Bone Miner Metab"},{"key":"779_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s007740170001","volume":"19","author":"H Orimo","year":"2001","unstructured":"Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K, Miyamoto S, Soen S, Nishimura J, Oh-Hashi Y, Hosoi T, Gorai I, Tanaka H, Igai T, Kishimoto H, Osteoporosis Diagnostic Criteria Review Committee: Japanese Society for Bone and Mineral Research (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331\u2013337","journal-title":"J Bone Miner Metab"},{"key":"779_CR13","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1007\/s00198-014-2991-z","volume":"26","author":"A Sakai","year":"2015","unstructured":"Sakai A, Ito M, Tomomitsu T, Tsurukami H, Ikeda S, Fukuda F, Mizunuma H, Inoue T, Saito H, Nakamura T, e-ADVANCED Study Group (2015) Efficacy of combined treatment with alendronate (ALN) and eldecalcitol, a new active vitamin D analog, compared to that of concomitant ALN, vitamin D plus calcium treatment in Japanese patients with primary osteoporosis. Osteoporos Int 26:1193\u20131202","journal-title":"Osteoporos Int"},{"key":"779_CR14","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s00223-011-9528-7","volume":"89","author":"AJ Brown","year":"2011","unstructured":"Brown AJ, Ritter CS (2011) The vitamin D analog 1\u03b1,25-dihydroxy-2\u03b2-(3-hydroxypropyloxy) vitamin D(3) (eldecalcitol) is a potent regulator of calcium and phosphate metabolism. Calcif Tissue Int 89:372\u2013378","journal-title":"Calcif Tissue Int"},{"key":"779_CR15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00774-014-0582-x","volume":"33","author":"N Sasaki","year":"2015","unstructured":"Sasaki N, Tsunoda M, Hashimoto N, Ikee R (2015) Efficacy and safety of eldecalcitol, a new active vitamin D3 analog, in the bone metabolism of postmenopausal women receiving maintenance hemodialysis. J Bone Miner Metab 33:213\u2013220","journal-title":"J Bone Miner Metab"},{"key":"779_CR16","doi-asserted-by":"crossref","first-page":"R154","DOI":"10.1186\/ar3107","volume":"12","author":"SY Kim","year":"2010","unstructured":"Kim SY, Schneeweiss S, Liu J, Daniel GW, Chang CL, Garneau K, Solomon DH (2010) Risk of osteoporotic fracture in a large population-based cohort of patients with rheumatoid arthritis. Arthritis Res Ther 12:R154","journal-title":"Arthritis Res Ther"},{"key":"779_CR17","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.3899\/jrheum.100363","volume":"37","author":"RJ Weiss","year":"2010","unstructured":"Weiss RJ, Wick MC, Ackermann PW, Montgomery SM (2010) Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases: a case-control study with 53,108 patients with fracture. J Rheumatol 37:2247\u20132250","journal-title":"J Rheumatol"},{"key":"779_CR18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s00198-015-3279-7","volume":"27","author":"Y Fan","year":"2016","unstructured":"Fan Y, Wei F, Lang Y, Liu Y (2016) Diabetes mellitus and risk of hip fractures: a meta-analysis. Osteoporos Int 27:219\u2013228","journal-title":"Osteoporos Int"},{"key":"779_CR19","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/aje\/kwm106","volume":"166","author":"M Janghorbani","year":"2007","unstructured":"Janghorbani M, Van Dam RM, Willett WC, Hu FB (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495\u2013505","journal-title":"Am J Epidemiol"},{"key":"779_CR20","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s00198-006-0253-4","volume":"18","author":"P Vestergaard","year":"2007","unstructured":"Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes\u2013a meta-analysis. Osteoporos Int 18:427\u2013444","journal-title":"Osteoporos Int"},{"key":"779_CR21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00198-013-2438-y","volume":"25","author":"CL Gregson","year":"2014","unstructured":"Gregson CL, Dennison EM, Compston JE, Adami S, Anderson Jr F, Adachi JD, Hooven FH (2014) Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int 25:85\u201395","journal-title":"Osteoporos Int"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00774-016-0779-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-016-0779-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-016-0779-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T21:07:41Z","timestamp":1498770461000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00774-016-0779-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10,3]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["779"],"URL":"https:\/\/doi.org\/10.1007\/s00774-016-0779-2","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,10,3]]}}}